Chronic late-gestation hypoglycemia upregulates hepatic PEPCK associated with increased PGC1α mRNA and phosphorylated CREB in fetal sheep

Paul J. Rozance,1 Sean W. Limesand,2 James S. Barry,1 Laura D. Brown,1 Stephanie R. Thorn,1 Dan LoTurco,1 Timothy R. H. Regnault,1,3 Jacob E. Friedman,1 and William W. Hay Jr.1

1Perinatal Research Center, Department of Pediatrics, School of Medicine, University of Colorado Denver and Health Sciences Center, Aurora, Colorado; 2Agricultural Research Complex, Department of Animal Sciences, University of Arizona, Tucson, Arizona; and 3Department of Obstetrics and Gynaecology, University of Western Ontario, London, Ontario, Canada

Submitted 2 October 2007; accepted in final form 29 November 2007

Rozance PJ, Limesand SW, Barry JS, Brown LD, Thorn SR, LoTurco D, Regnault TR, Friedman JE, Hay WW Jr. Chronic late-gestation hypoglycemia upregulates hepatic PEPCK associated with increased PGC1α mRNA and phosphorylated CREB in fetal sheep. Am J Physiol Endocrinol Metab 294:E365–E370, 2008. First published December 4, 2007; doi:10.1152/ajpendo.00639.2007.—Hepatic glucose production is normally activated at birth but has been observed in response to experimental hypoglycemia in fetal sheep. The cellular basis for this process remains unknown. We determined the impact of 2 wk of fetal hypoglycemia during late gestation on enzymes responsible for hepatic gluconeogenesis, focusing on the insulin-signaling pathway, transcription factors, and coactivators that regulate gluconeogenesis. Hepatic phosphoenolpyruvate carboxykinase and glucose-6-phosphatase mRNA increased 12-fold and 7-fold, respectively, following chronic hypoglycemia with no change in hepatic glycogen. Chronic hypoglycemia decreased fetal plasma insulin with no change in glucagon but increased plasma cortisol 3.5-fold. Peroxisome proliferator-activated receptor-γ coactivator-1α mRNA and phosphorylation of cAMP response element binding protein at Ser152 were both increased, with no change in Akt, forkhead transcription factor FoxO1, hepatocyte nuclear factor-4α, or CCAAT enhancer binding protein-β. These results demonstrate that chronic fetal hypoglycemia triggers signals that can activate gluconeogenesis in the fetal liver.

INTRAUTERINE GROWTH RESTRICTION (IUGR) affects 4–8% of newborns and is commonly associated with placental insufficiency and decreased fetal nutrient delivery (12, 45, 52). In addition to a wide variety of perinatal morbidities, IUGR increases the risk of developing several adult-onset metabolic diseases, including type 2 diabetes mellitus, a disease characterized by peripheral insulin resistance and insufficient insulin secretion (24, 49). One of the hallmarks of type 2 diabetes is reduced ability of insulin to suppress hepatic glucose production (22). It is significant, therefore, that in several animal models of IUGR there is an early and persistent increase in fetal and neonatal hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression, the enzyme that catalyzes the first committed step of gluconeogenesis (9, 21, 32, 42, 47, 65). The various nutrient and secondary metabolic abnormalities in IUGR fetuses that might cause such changes in liver enzyme function and glucose production are uncertain. The most common metabolic condition in all IUGR fetuses that would have direct bearing on hepatic glucose production is decreased placental glucose supply to the fetus and relative fetal hypoglycemia. Studies of experimental fetal hypoglycemia without placental insufficiency or global nutrient restriction, however, have shown variable results for induction of hepatic PEPCK (11, 20, 23, 40, 43), which may reflect species, timing/duration, and other methodological differences.

Among the complex network of transcription factors and cofactors that regulate PEPCK gene expression, peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) and cAMP response element binding protein (CREB) are particularly important effectors of the cAMP pathway. PGC1α does not bind directly to the PEPCK promoter. Instead it facilitates the transcriptional activity of hepatocyte nuclear factor (HNF) 4α, the glucocorticoid receptor, and forkhead transcription factor FoxO1 to increase PEPCK gene transcription (7, 37). CCAAT enhancer binding protein (C/EBP)α and C/EBPβ bind to the cAMP response element of the PEPCK promoter and play an important role in cAMP induction (7, 55). The prevailing model is that induction by cAMP is mediated by phosphorylation of CREB, which must interact with C/EBP and other factors bound to an upstream accessory enhancer to stimulate gene transcription (25, 38). Furthermore, CREB induces PGC1α mRNA expression (37). FoxO1, which is negatively regulated by insulin signaling through Akt via nuclear exclusion, also facilitates PEPCK gene expression (7).

To evaluate the impact of experimental hypoglycemia on fetal glucose metabolism, we previously used late-gestation hypoglycemic fetal sheep produced by a continuous maternal insulin infusion (10). This renders the fetus chronically hypoglycemic, and these fetal sheep increase endogenous glucose production, but the cellular basis for this response is unknown. Given the propensity for increased glucose production and its contribution to the risk for type 2 diabetes among IUGR offspring, it is important to understand the cellular mechanisms responsible for increased hepatic glucose production in response to fetal hypoglycemia.

MATERIALS AND METHODS

Animal model and organ isolation. Studies were conducted in pregnant Columbia-Rambouillet ewes (singleton) during the final 20% of gestation (term of 147 days). Indwelling catheters were

http://www.ajpendo.org 0193-1849/08 $8.00 Copyright © 2008 the American Physiological Society E365

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
surgically placed into the ewe and fetus as previously described (34, 56). All animal procedures were in compliance with guidelines of the United States Department of Agriculture, the National Institutes of Health, and the American Association for the Accreditation of Laboratory Animal Care. The animal care and use protocols were approved by the University of Colorado Health Sciences Center Institutional Animal Care and Use Committee. Data for many of the animals used in this study have been reported, as described in RESULTS (34, 56). As previously described, animals were randomly placed into one of two groups: euglycemic control (C) animals (n = 15) or hypoglycemic (H) animals (n = 16). The H ewes received a 2-wk intravenous insulin infusion (30–60 pmol min⁻¹ kg⁻¹, Humulin R; Eli Lilly, Indianapolis, IN) in 0.5% BSA (Sigma, St. Louis, MO) in 0.9% NaCl adjusted on average twice daily to produce a 50% reduction in maternal plasma glucose (from 60–70 to 30–35 mg/dl), which also decreased fetal glucose concentrations by 50%. The insulin infusion was started on day 122.5 ± 0.6 of gestation. Gestational ages at necropsy are given in Table 1.

Necropsies were performed as follows: the ewe and fetus were anesthetized with maternally administered intravenous ketamine (4.4 mg/kg) and diazepam (0.11 mg/kg). After ewes were hysterectomized, the fetus was removed, weighed, and dissected for organ weights. Sections of the right hepatic lobe were snap frozen in liquid nitrogen and then transferred to a −80°C freezer. The fetus was then euthanized by administering intravenous concentrated pentobarbital sodium (10 ml; Sleeppaway, Fort Dodge Animal Health, Fort Dodge, IA). The fetus died under anesthesia following an intracardiac injection of pentobarbital sodium (1 ml).

Biochemical analysis. Whole blood was collected in EDTA-coated syringes and was centrifuged (14,000 g) for 3 min at 4°C. Plasma was removed, and the glucose and lactate concentrations were determined by using the YSI model 2700 select biochemistry analyzer (Yellow Springs Instruments, Yellow Springs, OH). The remainder of the plasma was stored at −70°C for hormone measurements. Plasma insulin concentrations were measured by an ovine insulin ELISA (Alpco, Windham, NH; inter- and intra-assay coefficients of variation were 2.9 and 5.6%, respectively), and plasma cortisol concentrations were measured by a salivary cortisol ELISA (Alpco; inter- and intra-assay coefficients of variation were 5.7 and 4.4%, respectively). Blood oxygen content was determined by using an ABL 520 blood gas analyzer (Radiometer, Copenhagen, Denmark) (36).

Glycogen content. Hepatic glycogen content was determined as previously described, and results are expressed as milligrams of glycogen per gram liver (wet weight) (2).

Cloning and real-time PCR for relative gene expression. Total RNA was extracted from pulverized hepatic tissue (100 mg) and was reverse transcribed into cDNA as previously described (35). Cloning and real-time quantitative PCR for ovine ribosomal protein S15, PEPCK, glucose-6-phosphatase (G6Pase), and PGC1α (GenBank accession nos. AY949774, EF062862, EF062861, and AY957611, respectively) have been previously described (35, 57). cDNA samples were run in triplicate, and the quantitative PCR was performed as previously described (57) with the standard curve method of relative quantification used to compare results (66). S15 was used as a housekeeping gene and was not different between groups.

Protein extraction and Western blot analysis. Protein was extracted from pulverized hepatic tissue (200 mg) by the addition of 600 μl of ice-cold lysis buffer [150 mmol/l NaCl, 20 mmol/l Tris (pH 7.4), 1% vol/vol Nonidet P-40, 2 mmol/l EDTA, 2.5 mmol/l Na3PO4, 10% vol/vol glycerol, 20 mmol/l β-glycerophosphate, 0.575 mmol/l phenylmethylsulfonyl fluoride, 2% vol/vol Sigma mammalian protease inhibitor cocktail, and 0.5% vol/vol Sigma phosphate inhibitor] followed by 30 min on an orbital rocker at 4°C. The samples were then sonicated for 30 s, agitated, and placed on an orbital rocker for another 30 min at 4°C. The protein was separated from cellular debris by centrifugation at 21,000 g for 20 min at 4°C. The supernatant was removed, and the protein concentration was quantified with the BioRad DC protein assay (BioRad, Hercules, CA).

Equal amounts of protein were separated by polyacrylamide gel electrophoresis under reduced conditions (5% β-mercaptoethanol). Proteins were then transferred to a polyvinylidene difluoride membrane (Bio-Rad). Unless otherwise noted, all Western blot membranes were blocked for 1 h in phosphate-buffered saline with 0.1% Tween 20 (PBST; Bio-Rad) and 5% wt/vol nonfat dried milk (NFDM) for 1 h at room temperature. The following primary antibodies were diluted in PBST with 5% NFDM: C/EBPβ (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA), CREB (1:1,000, Santa Cruz Biotechnology), HNF4α (1:750, Santa Cruz Biotechnology), and β-actin (1:4,000, Medimmune, Gaithersburg, MD). Other primary antibodies were diluted in PBST with 5% BSA: Ser133-phosphorylated CREB (1:500, Cell Signaling Technology, Danvers, MA), Akt (1:500, Cell Signaling Technology), Ser73-phosphorylated Akt (1:500, Cell Signaling Technology), FoxO1 (1:250, Cell Signaling Technology), and Ser256-phosphorylated FoxO1 (1:500, Cell Signaling Technology). Membranes probed for insulin receptor β were blocked for 1 h at room temperature in PBST with 5% NFDM and with 1% BSA, and the primary antibody (Santa Cruz Biotechnology) was diluted 1:1,250 in the same buffer. Horseradish peroxidase-conjugated secondary antibodies were diluted in PBST with 5% NFDM and were applied to membranes for 1 h at room temperature. Immunocomplexes were detected with enhanced chemiluminescence (ECL Plus, Amersham, Piscataway, NJ). Densitometry was performed by using Scion Image software (Scion, Frederick, MD). All results were normalized to β-actin to control for loading differences, and a reference sample was analyzed on every membrane to control for differences in transfer efficiency. Ser73-phosphorylated Akt and Ser256-phosphorylated FoxO1 also were normalized to the total amount of each protein. Antibodies were stripped from the membranes with Restore Western stripping buffer (Pierce, Rockford, IL).

Statistical analysis. Statistical analysis was performed with SAS version 9.1 (58). All results are presented as means ± SE. Groups were compared by using either the Student’s t-test (parametric) or the Mann-Whitney test (nonparametric), both two tailed, and a level of 0.05 or less was considered significant.

RESULTS

Fetal characteristics. Information on the experimental conditions and necropsy measurements have been previously reported for many of the fetuses used in these experiments (34, 56). Characteristics for the group of fetuses used in this study are summarized in Table 1. We previously reported (34) no difference in fetal arterial plasma glucagon, epinephrine, or norepinephrine concentrations between the groups. Reported here for the first time (Table 1), fetal arterial plasma cortisol

Table 1. Fetal characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Hypoglycemic</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age, days</td>
<td>138.6 ± 0.3</td>
<td>138.8 ± 0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>4.380 ± 0.116</td>
<td>3.370 ± 0.137*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Liver weight, g</td>
<td>121.96 ± 5.55</td>
<td>93.19 ± 5.54*</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Liver/body weight, %</td>
<td>2.78 ± 0.09</td>
<td>2.80 ± 0.12</td>
<td>NS</td>
</tr>
<tr>
<td>Glucose, mmol/l</td>
<td>1.12 ± 0.03</td>
<td>0.58 ± 0.02*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Lactate, mmol/l</td>
<td>1.98 ± 0.16</td>
<td>1.33 ± 0.10*</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Oxygen, mmol/l</td>
<td>3.20 ± 0.17</td>
<td>4.15 ± 0.18*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin, ng/ml</td>
<td>0.32 ± 0.04</td>
<td>0.12 ± 0.02*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cortisol, ng/ml</td>
<td>5.3 ± 0.7</td>
<td>19.0 ± 4.2*</td>
<td>&lt;0.0005</td>
</tr>
</tbody>
</table>

Values are means ± SE. *Significant difference between hypoglycemic and control fetuses by Student’s t-test (parametric) or Mann-Whitney test (nonparametric), NS, not significant.
concentrations are significantly greater (3.5-fold increase, \( P < 0.0005 \)) in the H group than in the C group. The percent of male fetuses was not statistically different (60% C, 40% H), and there was no distinguishable effect of fetal sex on any measurements.

**G6Pase and PEPCK mRNA expression and glycogen content.** PEPCK mRNA was significantly greater (12-fold, \( P < 0.05 \)) in H fetal livers compared with C fetuses (Fig. 1A). The same expression pattern was found for G6Pase mRNA (7-fold increase, \( P < 0.0005 \), Fig. 1B). Chronic fetal hypoglycemia did not affect hepatic glycogen content (Fig. 2).

**Insulin receptor and Akt.** Hepatic content of the \( \beta \)-subunit of the insulin receptor was significantly higher (34% increase) in H fetuses compared with C fetal livers (\( P < 0.001 \), Fig. 3, A and B). There were no differences in the hepatic content of Akt (1.00 \( \pm \) 0.13 C, 0.87 \( \pm \) 0.09 H, arbitrary units relative to C) or in the ratio of Akt phosphorylated at the serine 473 position to total Akt (1.00 \( \pm \) 0.23 C, 1.17 \( \pm \) 0.29 H, arbitrary units relative to C).

**Transcription factors and transcription coactivators CREB, \( \alpha \)-CEBP\( \beta \), HNF4\( \alpha \), FoxO1, and PGC1\( \alpha \).** There was a significantly lower amount of total CREB (38% decrease) present in H livers compared with C fetal livers (\( P < 0.001 \), Fig. 3, A and C). The ratio of phosphorylated (active) CREB on serine 133 to total CREB was twofold higher in H fetal livers compared with C fetal livers (\( P < 0.01 \), Fig. 3, A and D). \( \alpha \)-CEBP\( \beta \) (1.00 \( \pm \) 0.08 C, 1.12 \( \pm \) 0.12 H, arbitrary units relative to C), HNF4\( \alpha \) (1.00 \( \pm \) 0.16 C, 0.88 \( \pm \) 0.17 H, arbitrary units relative to C), FoxO1 (1.00 \( \pm \) 0.10 C, 0.94 \( \pm \) 0.11 H, arbitrary units relative to C), and the ratio of FoxO1 phosphorylated at the serine 256 position to total FoxO1 (1.00 \( \pm \) 0.08 C, 0.77 \( \pm \) 0.09 H, arbitrary units relative to C) were not different between groups. PGC1\( \alpha \) mRNA was 2.5-fold greater in H compared with C fetal livers (\( P < 0.05 \), Fig. 1C).

**DISCUSSION**

The major finding in the present study is that fetal glucose deprivation activates hepatic PEPCK and G6Pase mRNA expression. Fetal hypoglycemia does not affect hepatic glycogen content. This demonstrates that fetal glucose production following chronic hypoglycemia is due to sustained gluconeogenesis as previously postulated (10) and not to persistent glycogenolysis. Normally, hepatic gluconeogenesis in fetal sheep does not occur until very late in gestation, when it develops in response to a surge in fetal cortisol secretion, which occurs at gestational ages beyond the time point used in this study (18, 19). The central role of fetal cortisol secretion in activating glucose production has been determined by studies showing that hypophysectomy in fetal sheep renders them incapable of increasing plasma cortisol concentrations. Such fetuses have significantly decreased hepatic activities of gluconeogenic enzymes. Furthermore, fetal cortisol infusions increase these enzyme activities (17, 18). Our data suggest that fetal hypoglycemia increases fetal cortisol production and plasma concentrations and induces both PGC1\( \alpha \) mRNA and phosphorylated CREB, all of which are important regulatory components in the gluconeogenic response.

In our model, glucagon and epinephrine concentrations are not elevated, although the insulin-to-glucagon ratio is decreased (34). Plasma cortisol is higher, and excess glucocorticoids increase PEPCK gene expression directly and act permissively to augment induction by other stimuli (6). Glucagon, a decrease in the insulin-to-glucagon ratio, or epinephrine, activates CREB by stimulating phosphorylation at position 133, which in turn increases expression of the nuclear coactivator PGC1\( \alpha \) as well as directly increasing PEPCK and G6Pase expression (27, 54, 60). Insulin, in contrast, suppresses hepatic PGC1\( \alpha \) transcriptional activity in part via Akt-mediated phosphorylation and nuclear export of the forkhead family

![Fig. 1. Hepatic mRNA concentrations. Phosphoenolpyruvate carboxykinase (PEPCK; A), glucose-6-phosphatase (G6Pase; B), and peroxisome proliferator-activated receptor-\( \gamma \) coactivator-\( \alpha \) (PGC1\( \alpha \); C) mRNA concentrations were determined in livers from control and hypoglycemic fetuses by real-time quantitative PCR. Data are means \( \pm \) SE normalized to ribosomal protein S15 and are presented as fold change relative to control fetuses. Treatment groups are listed on x-axis. *Higher amount of PEPCK (\( P < 0.05 \)), G6Pase (\( P < 0.0005 \)), and PGC1\( \alpha \) (\( P < 0.05 \)) in hypoglycemic livers compared with control livers. All statistics are from Mann-Whitney test for non-parametric analysis.](http://ajpendo.physiology.org/)
activator FoxO1 (50). In addition, insulin has recently been shown to stimulate phosphorylation of PGC1α directly to inhibit its ability to activate PEPCK gene transcription (33). Given that we found no changes in the distal insulin-signaling targets, either phosphorylated FoxO1 or Akt, our results suggest that the upregulation of PEPCK during hypoglycemia was more likely due to increased activation by cortisol and a decrease in the insulin-to-glucagon ratio through either CREB or PGC1α, rather than a reduction in insulin signaling.

The increase in PGC1α mRNA by chronic fetal hypoglycemia is similar to the findings in the bilateral uterine artery ligation model of IUGR in the rat, in which both PGC1α and PEPCK mRNA are increased (32). In addition to PGC1α, we also measured other factors that are known to increase PEPCK and G6Pase expression and activity, including C/EBPβ and HNF4α (5, 8, 53). However, neither of these factors was increased by chronic fetal hypoglycemia. An interesting negative result was no change in HNF4α because it differs from fetal rats exposed to exogenous glucocorticoids. These fetuses have increased hepatic concentrations of PEPCK and HNF4α mRNA but normal hepatic concentrations of PGC1α (41). In our model of fetal hypoglycemia, with increased endogenous fetal glucocorticoids, hepatic PEPCK and PGC1α mRNA are increased but HNF4α protein is not different. These differences suggest that the surge in fetal cortisol may not be the sole mechanism upregulating PEPCK in the hypoglycemic fetal sheep.

The maintenance of hepatic glycogen content in the hypoglycemic group, despite a lower insulin concentration and decreased glycogenic precursors (glucose and lactate), confirms the results of some earlier fetal experiments but is in conflict with others. Several experimental models of IUGR and nutrient deprivation have demonstrated decreased hepatic glycogen (4, 39, 43, 44, 46). In each of these models, when reported, fetal oxygen values (partial pressure, hemoglobin-oxygen saturation, or blood oxygen content) either are normal or decreased and fetal plasma glucagon concentration is increased. It is possible that the increased fetal oxygenation in our hypoglycemic group allows for maintenance of hepatic glycogen. When tested in late-gestation fetal sheep, hypoxemia without hypoglycemia decreases fetal hepatic glycogen content (63). Another difference between this model and the models in which hepatic glycogen decreases is that fetal glucagon is not elevated in the hypoglycemic group (34). In a different late-gestation fetal sheep model of nutrient deprivation, fetuses subjected to a five-day maternal fast had significantly lower fetal weight and maternal hepatic glycogen content but did not have different fetal glucagon concentrations or hepatic glycogen contents (29, 59). In addition, piglets did not have lower liver glycogen contents following a maternal fast for the final 7 or 21 days of gestation (15), and unilateral ligation of the uterine artery in guinea pigs produced IUGR fetuses that had increased hepatic glycogen content (31). Our results are consistent with the studies that demonstrate no decrease in hepatic glycogen following fetal nutrient deprivation, but there clearly are variations among studies.

Cortisol is important for hepatic glycogen accumulation, and at gestational ages beyond 135 days, fetal sheep plasma cortisol is almost entirely of fetal origin (26). Increased cortisol
concentrations in response to hypoglycemia have been described before in a variety of late-gestation and neonatal mammals (13, 28, 62). In the sheep, like many mammalian species, liver glycogen content increases during the later part of gestation (61). The increase in hepatic glycogen during the last part of gestation is dependent on cortisol (1, 51, 64), and in fact exogenous cortisol can augment and accelerate late-gestation hepatic glycogen synthesis and deposition (3, 16, 30, 64). These results have been confirmed with in vitro studies using fetal liver explants and primary fetal hepatocytes, which show that glucocorticoids are necessary for allowing insulin-stimulated glycogen synthesis and deposition (14, 48, 64).

In conclusion, 2 wk of experimental hypoglycemia in late-gestation fetal sheep increases hepatic PEPCk and G6Pase mRNA and stimulates hepatic glucose output (10). This is associated with increased fetal plasma cortisol concentrations, increased hepatic PGC1α mRNA, and activation of hepatic CREB. In addition, fetal hepatic glycogen content is maintained despite decreased insulin and glycogen precursors. However, hepatic glucose production was not enough to restore fetal glucose concentrations to normal, indicating that maternal glucose supply to the fetus is a critical factor regulating fetal glucose concentrations.

REFERENCES

32. Lane RH, MacLennan NK, Hsu JL, Janke SM, Pham TD. Increased hepatic peroxisome proliferator-activated receptor-gamma coactivator-1


